1. Scrip

Genmab Confident It Has Edge Over Roche In Bispecific Battle

Epcoritamab Tipped To Lead Rival CD20xCD3 Drugs

 
• By Andrew McConaghie

Genmab may only recently have launched its first commercial operations with Tivdak, but is stepping up to co-market epcoritamab with AbbVie against the might of Roche in the new CD20xCD3 field.

Genmab Office Copenhagen - close up
Genmab only recently launched its commercial division with Tivdak, but is now preparing for a possible 2023 launch of epcoritamab. • Source: Genmab

Executives at Genmab are confident that the firm has an edge over Roche in the new class of CD20xCD3 bispecific antibody lymphoma therapies, although it could still be beaten to the US market by their rivals.

Any advantage in terms of data will be important to Genmab and its partner AbbVie, in what is expected to be a closely contested market, and one that could see the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip